FORTE Subanalysis: Efficacy of KRd With or Without ASCT Followed by KR or R Maintenance in Patients With ND MM According to Cytogenetic Risk Status

Source: 2021 ASCO Virtual Annual Meeting*
Download Slideset
June 4-8, 2021; Online at https://conferences.asco.org/am
Results of this subgroup analysis show that KRd-ASCT, as compared with KRd12, and KR maintenance, as compared with R maintenance, prolonged PFS across all cytogenetic risk groups except patients with amp(1q).
Format: Microsoft PowerPoint (.ppt)
File Size: 458 KB
Released: June 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings